CoChat

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the pharmacological properties of JTE-052, a novel Janus kinase (JAK) inhibitor. METHODS: The JAK inhibitory activity of JTE-052 was evaluated using recombinant human enzymes. The inhibitory effects on cytokine signaling pathways were evaluated using primary human inflammatory cells. The in vivo efficacy and potency of JTE-052 were examined in a mouse interleukin (IL)-2-induced interferon (IFN)-γ production model and a rat collagen-induced arthritis model. RESULTS: JTE-052 inhibited the JAK1, JAK2, JAK3, and tyrosine kinase (Tyk)2 enzymes in an adenosine triphosphate (ATP)-competitive manner and inhibited cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage colony-stimulating factor, and IFN-α. JTE-052 inhibited the activation of inflammatory cells, such as T cells, B cells, monocytes, and mast cells, in vitro. Oral dosing of JTE-052 resulted in potent suppression of the IL-2-induced IFN-γ production in mice with an ED50 value of 0.24 mg/kg, which was more potent than that of tofacitinib (ED50 = 1.1 mg/kg). In the collagen-induced arthritis model, JTE-052 ameliorated articular inflammation and joint destruction even in therapeutic treatments where methotrexate was ineffective. CONCLUSIONS: The present results indicate that JTE-052 is a highly potent JAK inhibitor, and represents a candidate anti-inflammatory agent for suppressing various types of inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00011-014-0782-9

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Inhibitory effects of JTE-052 on JAK enzymes. Enzyme assays were performed using the kinase domains of recombinant human JAK enzymes, a biotinylated peptide substrate, and [33P]ATP. a Inhibitory effects were determined at an ATP concentration equivalent to the apparent Km for each enzyme. b Lineweaver–Burk linear transformations were plotted for 0 (filled circles), 1 (open triangles), 2 (filled squares), 4 (open circles), 8 (filled triangles), 16 (open squares), 32 (crosses), and 64 nM (open diamonds) JTE-052. Three independent experiments were performed. Values are mean ± SEM (a). Representative data are shown from three independent experiments (b)
Fig. 1 Inhibitory effects of JTE-052 on JAK enzymes. Enzyme assays were performed using the kinase domains of recombinant human JAK enzymes, a biotinylated peptide substrate, and [33P]ATP. a Inhibitory effects were determined at an ATP concentration equivalent to the apparent Km for each enzyme. b Lineweaver–Burk linear transformations were plotted for 0 (filled circles), 1 (open triangles), 2 (filled squares), 4 (open circles), 8 (filled triangles), 16 (open squares), 32 (crosses), and 64 nM (open diamonds) JTE-052. Three independent experiments were performed. Values are mean ± SEM (a). Representative data are shown from three independent experiments (b)CC BY · PubMed Central
Fig. 2 Inhibitory effects of JTE-052 on cytokine signaling. hPBMCs were stimulated with IL-2 (100 ng/mL), IL-6 (100 ng/mL), IL-23 (100 ng/mL), GM-CSF (1 ng/mL), or IFN-α (100 ng/mL) for 15 min in the presence or absence of JTE-052. The phosphorylation levels of Stat5 (IL-2 and GM-CSF), Stat3 (IL-6 and IL-23), or Stat1 (IFN-α) in CD3+CD4+ cells (IL-2, IL-23, and IFN-α) or CD3-CD4+ cells (IL-6 and GM-CSF) were analyzed by flow cytometry. Data are presented as percentages of mean fluorescence intensity relative to vehicle (100 %) and non-stimulated control cells (0 %). Values are mean ± SEM. Three independent experiments were performed
Fig. 2 Inhibitory effects of JTE-052 on cytokine signaling. hPBMCs were stimulated with IL-2 (100 ng/mL), IL-6 (100 ng/mL), IL-23 (100 ng/mL), GM-CSF (1 ng/mL), or IFN-α (100 ng/mL) for 15 min in the presence or absence of JTE-052. The phosphorylation levels of Stat5 (IL-2 and GM-CSF), Stat3 (IL-6 and IL-23), or Stat1 (IFN-α) in CD3+CD4+ cells (IL-2, IL-23, and IFN-α) or CD3-CD4+ cells (IL-6 and GM-CSF) were analyzed by flow cytometry. Data are presented as percentages of mean fluorescence intensity relative to vehicle (100 %) and non-stimulated control cells (0 %). Values are mean ± SEM. Three independent experiments were performedCC BY · PubMed Central
Fig. 3 Inhibitory effects of JTE-052 on the activation of various inflammatory cells. a Human T cells pretreated with PHA were stimulated with IL-2 (20 ng/mL) for 3 days in the presence of JTE-052. b Human B cells were stimulated with IL-21 (10 ng/mL) and anti-CD40 antibody (1 μg/mL) for 3 days in the presence of JTE-052. Proliferation was estimated using [3H]thymidine. c Human monocytes were stimulated with GM-CSF (0.03 ng/mL) for 16 h in the presence of JTE-052, and then stimulated with LPS (0.1 ng/mL) for an additional 6 h. d Human mast cells were stimulated with IL-4 (10 ng/mL) and IgE (1 μg/mL) for 5 days in the presence of JTE-052, and simulated with anti-IgE antibody (1 μg/mL) for an additional 5 h. The amounts of TNF-α in the supernatants were measured by ELISA. Three independent experiments using cells from different donors were performed. Values are the means of 3–6 samples from one representative experiment
Fig. 3 Inhibitory effects of JTE-052 on the activation of various inflammatory cells. a Human T cells pretreated with PHA were stimulated with IL-2 (20 ng/mL) for 3 days in the presence of JTE-052. b Human B cells were stimulated with IL-21 (10 ng/mL) and anti-CD40 antibody (1 μg/mL) for 3 days in the presence of JTE-052. Proliferation was estimated using [3H]thymidine. c Human monocytes were stimulated with GM-CSF (0.03 ng/mL) for 16 h in the presence of JTE-052, and then stimulated with LPS (0.1 ng/mL) for an additional 6 h. d Human mast cells were stimulated with IL-4 (10 ng/mL) and IgE (1 μg/mL) for 5 days in the presence of JTE-052, and simulated with anti-IgE antibody (1 μg/mL) for an additional 5 h. The amounts of TNF-α in the supernatants were measured by ELISA. Three independent experiments using cells from different donors were performed. Values are the means of 3–6 samples from one representative experimentCC BY · PubMed Central
Fig. 4 In vivo potency of JTE-052. DBA/1J mice (n = 5–10) were dosed with vehicle, JTE-052, or tofacitinib. After 1 or 6 h, they were injected with IL-2 and anti-mouse IFN-γ capture antibody. At 6 h after the injection, blood samples were collected, and the serum IFN-γ levels were measured. Values are mean ± SD
Fig. 4 In vivo potency of JTE-052. DBA/1J mice (n = 5–10) were dosed with vehicle, JTE-052, or tofacitinib. After 1 or 6 h, they were injected with IL-2 and anti-mouse IFN-γ capture antibody. At 6 h after the injection, blood samples were collected, and the serum IFN-γ levels were measured. Values are mean ± SDCC BY · PubMed Central
Fig. 5 Preventive effects of JTE-052 on collagen-induced arthritis in a rat model. Rats (n = 10) were orally administered vehicle, JTE-052 (0.1, 1, or 10 mg/kg), or MTX (0.3 mg/kg) once daily for 3 weeks from the day of the first collagen injection. The hind paw volume (a) and body weight (b) were measured periodically. Images of hematoxylin and eosin staining (c) and radiographs of hindlimbs (e) are shown. Histological change (d) and radiographical change (f) were scored. The results are expressed as mean ± SD. # p < 0.05, ## p < 0.01, versus vehicle by the Steel test
Fig. 5 Preventive effects of JTE-052 on collagen-induced arthritis in a rat model. Rats (n = 10) were orally administered vehicle, JTE-052 (0.1, 1, or 10 mg/kg), or MTX (0.3 mg/kg) once daily for 3 weeks from the day of the first collagen injection. The hind paw volume (a) and body weight (b) were measured periodically. Images of hematoxylin and eosin staining (c) and radiographs of hindlimbs (e) are shown. Histological change (d) and radiographical change (f) were scored. The results are expressed as mean ± SD. # p < 0.05, ## p < 0.01, versus vehicle by the Steel testCC BY · PubMed Central
Fig. 6 Therapeutic effects of JTE-052 on collagen-induced arthritis in a rat model. Rats with clinical signs of joint inflammation were randomized (n = 10) and orally administered vehicle, JTE-052 (0.1, 1, or 10 mg/kg), or MTX (0.3 mg/kg) once daily for 2 weeks from day 15. The hind paw volume (a) and body weight (b) were measured periodically. Images of hematoxylin and eosin staining (c) and radiographs of hindlimbs (e) are shown. Histological change (d) and radiographical change (f) were scored. The results are expressed as mean ± SD. *p < 0.05, **p < 0.01, versus vehicle by Dunnett’s test. # p < 0.05, ## p < 0.01, versus vehicle by the Steel test
Fig. 6 Therapeutic effects of JTE-052 on collagen-induced arthritis in a rat model. Rats with clinical signs of joint inflammation were randomized (n = 10) and orally administered vehicle, JTE-052 (0.1, 1, or 10 mg/kg), or MTX (0.3 mg/kg) once daily for 2 weeks from day 15. The hind paw volume (a) and body weight (b) were measured periodically. Images of hematoxylin and eosin staining (c) and radiographs of hindlimbs (e) are shown. Histological change (d) and radiographical change (f) were scored. The results are expressed as mean ± SD. *p < 0.05, **p < 0.01, versus vehicle by Dunnett’s test. # p < 0.05, ## p < 0.01, versus vehicle by the Steel testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 117

Metadata

Authors
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., & Matsushita, M.
Affiliations
Japan Tobacco (Japan) (JP)
Corresponding author
Tanimoto, Atsuo
Venue
Inflammation Research
Published
2014-11-12
Volume
64
Issue
1
Pages
41-51
ISSN
  • 1023-3830 (ISSN-L)
  • 1420-908X
OpenAlex
W1966518661
Cited by
111
References
23
Citations by year
2026: 9 · 2025: 21 · 2024: 7 · 2023: 8 · 2022: 17 · 2021: 15 · 2020: 13 · 2019: 8 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 3
FWCI
1.45
Type
journal article
Language
en
Open access
Locations
  • Inflammation Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
JAK inhibitors, Janus kinase, JAK1, JAK2, JAK3, TYK2, cytokine signaling, interleukin-2, interleukin-6, IL-23, interferon-gamma, collagen-induced arthritis, articular inflammation, joint destruction, anti-inflammatory agents, tofacitinib, oral bioavailability, pharmacokinetics
MeSH terms
Animals, Anti-Inflammatory Agents, Arthritis, Experimental, B-Lymphocytes, Cells, Cultured, Collagen, Disease Models, Animal, Humans, Inflammation, Interferon-gamma, Interleukin-2, Mast Cells, Methotrexate, Mice, Inbred DBA, Rats, Inbred Lew, T-Lymphocytes, Signal Transduction, Cytokines, Antirheumatic Agents, Protein Kinase Inhibitors, Mice, Rats, Janus Kinases, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. https://app.cochat.ai/papers/10.1007/s00011-014-0782-9
The paper
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., & Matsushita, M. (2015). Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflammation Research. https://doi.org/10.1007/s00011-014-0782-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.